Vinpotropil - instructions for use, doses, side effects, contraindications

Active substanceVinpocetine + PyracetamVinpocetine + Pyracetam

Similar drugsTo uncover

Vinpotropil®

concentrate in / in

CANONFARMA PRODUCTION, CJSC Russia

Vinpotropil®

capsules inwards

CANONFARMA PRODUCTION, CJSC Russia

Vinpotropil®

pills inwards

CANONFARMA PRODUCTION, CJSC Russia

Dosage form: & nbspcapsules

Composition:

1 capsule contains active substances: vinpocetine 5 mg, piracetam 400 mg; Excipients: lactose (milk sugar), talc.

The composition of the capsule body is gelatin: titanium dioxide, dye quinoline yellow, dye sunset yellow, gelatin;

composition of capsule cover gelatin: titanium dioxide, dye azorubin, gelatin.

Description:Capsules № 0 yellow with a lid of red color. The contents of capsules are white or almost white powder. Presence of separate crystals and lumps is allowed.

Pharmacotherapeutic group:Nootropic and cerebral blood flow improver

ATX: & nbsp

N.06.B.X.18 Vinpocetine

N.06.B.X.03 Pyracetam

Pharmacodynamics:

Vinpotropil® is a combined preparation. Possesses the properties characteristic for the agent improving cerebral blood flow (vinpocetine) and for a nootropic agent (piracetam).

As a means of improving cerebral blood flow:

Improves the metabolism of the brain, increasing the intake of glucose and oxygen by brain tissue.Increases the resistance of neurons to hypoxia; enhances the transport of glucose - to the brain, through the blood-brain barrier; translates the process of the decay of glucose into an energetically more economical, aerobic pathway; selectively blocks Ca2 + -dependent phosphodiesterase; increases the levels of adenosine monophosphate (AMP), cyclic guanosine monophosphate (cGMP) and adenosine triphosphate (ATP) of the brain. Increases the exchange of norepinephrine and serotonin of the brain; stimulates the ascending branch of the noradrenergic system, has an antioxidant effect. Reduces platelet aggregation and increased blood viscosity; increases the elasticity of erythrocytes and blocks the utilization of adenosine by erythrocytes; helps to increase the return of oxygen in the erythrocytes. Increases cerebral blood flow; reduces the resistance of cerebral vessels without a significant change in the indices of the systemic circulation. Does not have the effect of "stealing" and enhances blood supply, especially in ischemic areas of the brain. Penetrates through the placental barrier.

As a nootropic agent:

Has a positive effect on brain metabolic processes, slightly increases the concentration of ATP in the brain, enhances the synthesis of ribonucleic acid and phospholipids, stimulates glycolytic processes, enhances the utilization of glucose; improves the integrative activity of the brain, promotes memory consolidation, facilitates the learning process; changes the speed of propagation of excitation in the brain, improves microcirculation, without providing a vasodilating action, inhibits the aggregation of activated platelets; has a protective effect in brain damage caused by hypoxia, intoxication, electric shock; strengthens alpha and beta activity, reduces delta activity on the electroencephalogram, reduces the severity of the vestibular nystagmus; improves the connections between the cerebral hemispheres and synaptic conductivity in neocortical structures, increases mental activity, enhances cerebral blood flow; does not have sedative, psycho-stimulating effect. The effect develops gradually.

Has a pronounced effect on symptoms of initial manifestations of cerebral vascular cognitive impairmentgenesis in patients of elderly and senile age. It is recommended in psychogeriatric practice.

Pharmacokinetics:

Vinpocetine is rapidly absorbed. Time to reach the maximum concentration in blood plasma - 1 hour. Absorption occurs mainly in the proximal parts of the gastrointestinal tract. When passing through the wall of the intestine is not exposed to metabolism. The maximum concentration in tissues is noted 2-4 hours after ingestion. Linkage with proteins - 66%, bioavailability with ingestion - 7%. Clearance 66.7 l / h, exceeds the plasma volume of the liver (50 l / h), which indicates an extrahepatic metabolism. With repeated administration, the kinetics is linear. The half-life in humans is 4.83 ± 1.29 hours. It is excreted by the kidneys and through the intestine in a ratio of 3: 2.

Piracetam after ingestion is well absorbed and penetrates into various organs and tissues. Bioavailability is about 95%. The maximum concentration in the blood is reached after 0.5-1.0 h after ingestion. It penetrates the hemato-encephalic barrier, accumulates in the brain tissue 1-4 h after ingestion. From the cerebrospinal fluid is derived much more slowly than from other tissues. Virtually does not undergo biotransformation and 2/3 is excreted by the kidneys unchanged for 30 hours.The half-life from the plasma is 4.5 hours, from the brain -7.7 hours.

Indications:Insufficiency of cerebral circulation (the recovery period of ischemic and hemorrhagic stroke), encephalopathy of various genesis, including alcoholism; Parkinsonism of vascular genesis, intoxication, brain trauma and other diseases of the central nervous system, accompanied by a decline in intellectual-mnestic functions; psychoorganic syndrome with predominance of asthenia and adynamia, asthenic syndrome; labyrinthopathy, Meniere's syndrome; prevention of migraine and kinetosis.

Contraindications:

Hypersensitivity, pregnancy, lactation, severe cardiac arrhythmias, coronary heart disease (severe course), acute stage of hemorrhagic stroke, renal and / or hepatic insufficiency, children under 18 years of age (due to insufficient data).

Patients with rare hereditary diseases, such as galactose intolerance, lactase deficiency or glucose-galactose malabsorption should not take the drug.

Carefully:

Violation of hemostasis, heavy bleeding, benign hyperbilirubinemia (including Gilbert's syndrome), viral hepatitis, alcoholic liver disease, alcohol abuse, lack of glucose-6-phosphate dehydrogenase, epilepsy, old age.

Dosing and Administration:

For patients 18 years and older: inside, before eating 1-2 capsules 2-3 times a day. Last reception - 4 hours before bedtime. Maintenance dose -1 capsule 3 times a day. Duration of treatment is from 2-3 weeks to 2-6 months. Before cancellation, the dose should be gradually reduced.

Side effects:

From the side of the cardiovascular system: ECG change (segment depression ST, lengthening the interval QT), tachycardia, extrasystole, lability of blood pressure, sensation of "hot flashes".

From the central nervous system: sleep disturbances, headache, dizziness, mental stimulation, motor disinhibition, irritability, imbalance, reduced ability to concentrate, anxiety, depression, ataxia, extrapyramidal disorders (including hyperkinesia), convulsions, tremor.

On the part of the digestive system: gastralgia, nausea, vomiting, diarrhea, dry mouth, heartburn.

Others: allergic reactions, increased sexual activity, worsening angina, weight gain, asthenia, general weakness, increased sweating.

Overdose:

Symptoms: increased severity of side effects.

Treatment: gastric lavage, reception of activated charcoal, symptomatic therapy.

Interaction:

Increases: risk of hemorrhagic complications against heparin therapy, effects of thyroid hormones, antipsychotics (neuroleptics), indirect anticoagulants, psychostimulants.

Reduces: effect of anticonvulsants (reduces the convulsive threshold).

Despite the lack of data confirming the possibility of interaction, it is recommended to exercise caution when concurrently administering with the drugs central, antiarrhythmic action.

Special instructions:

Presence of the syndrome of the prolonged interval QT and taking medications that elongate the interval QT, requires periodic ECG monitoring. In case of lactose intolerance, it should be taken into account that one tablet contains about 225 mg of lactose.

Effect on the ability to drive transp. cf.and fur:

Taking into account possible side effects, you should be careful when driving a car and working with mechanisms.

Form release / dosage:

Capsules.

Packaging:

For 10 or 15 capsules in a contour mesh package.

For 2, 3, 5 or 10 contour cell packs of 10 capsules or 2, 4, 6 or 8 contiguous cell packs of 15 capsules together with instructions for use in a pack of cardboard.

Storage conditions:

At a temperature of no higher than 25 ° C in the manufacturer's packaging. Keep out of the reach of children.

Shelf life:

4 years.

Do not use after the expiration date printed on the package.

Terms of leave from pharmacies:On prescription

Registration number:P N002632 / 01

Date of registration:15.05.2009 / 08.10.2015

Expiration Date:Unlimited

The owner of the registration certificate:CANONFARMA PRODUCTION, CJSC CANONFARMA PRODUCTION, CJSC Russia

Manufacturer: & nbsp

CANONFARMA PRODUCTION, CJSC Russia

Information update date: & nbsp16.02.2017

Illustrated instructions

Instructions

Vinpotropil® (Vinpotropile®)